MedChem Australia – catalysing value creation in drug discovery

  • Stupple, Paul (Primary Chief Investigator (PCI))
  • Charman, Susan (Chief Investigator (CI))
  • Lessene, Guillaume (Chief Investigator (CI))
  • Kassiou, Michael (Chief Investigator (CI))
  • Mitchell, Jeff (Chief Investigator (CI))
  • Newman, Stuart (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Australia has an enviable reputation in fundamental biology, but a poor record in translating discoveries into commercially attractive drug candidates. MedChem Australia (MCA) will bring together three leading medicinal chemistry groups to guide early-stage projects through the critical value creation steps where ‘hits’ are optimized to drug candidates with enhanced commercial value. These candidates are significantly more attractive to industry, and will catalyze investment to develop home grown, high value medicines, jobs and exports. MCA will deliver preclinical candidates, at least 3 new spinouts, and will engage actively with industry to drive investment and investment returns generating $15M in revenue and 15 new jobs over 5 years.
StatusActive
Effective start/end date30/06/23 → 6/12/28

Funding

  • Therapeutic Innovation Australia Limited
  • Monash University
  • Walter and Eliza Hall Institute of Medical Research (WEHI)
  • University of Sydney